News

The primary endpoint of the study was the rate of complete remission with or without recovery of normal blood counts. In Accede trial, a regimen of AS1413 and

The transaction is expected to get closed by the end of February 2011. With is acquisition, Oxford BioMedica will have greater control of the production of its proprietary

Both the parties said that a research scientist at HUMC, Antoine Carlisle, will be the principal investigator for this research. Oxygen Biotherapeutics chief medical officer Gerald Klein said

The FDA approval was supported by the result from a pivotal Phase III trial data which evaluated the safety and immunogenicity of Menveo against each of the four

Earlier, Pfizer and Morphosys tied up in December 2003 to develop therapeutic antibodies. Both the parties further extended their collaboration in 2006 under which Pfizer secured an option

AMT holds the commercialization rights to the AIP gene therapy (AMT-021). Under this grant, AMT expects to obtain EUR1.1m, which will cover almost 75% of AMT’s overall development

This agreement allows the companies to develop a total of eight ‘discovery phase’ candidates by combining an equal number of programmes. It also permits both the companies to

The approval follows the approval of Rituxan for this indication by the European Commission in October 2010. The FDA approval was based on a Phase III study, which

The once daily tablet, Gralise is developed by Depomed and it is licensed to Abbott Products in US, Mexico and Canada. Depomed CEO Carl Pelzel said the approval